Adial Pharmaceuticals Comments on Article in ‘The Atlantic,’ Highlighting the Second Pandemic of Addiction


CHARLOTTESVILLE, Va., June 07, 2021 (GLOBE NEWSWIRE) — ADial Pharmaceuticals (NASDAQ: ADIL; ADILW) (“Adial” or the “Firm”), a clinical-stage biopharmaceutical firm centered on creating therapies for the remedy and prevention of habit and associated issues, commends Kate Julian and The Atlantic for highlighting the key disaster going through our society in her article America Has a Drinking Problem. The article highlights the complexity of the components driving alcohol use and its pervasiveness in human society and, significantly, in america.

William Stilley, Chief Government Officer of Adial, commented, “We recognize the highlight that Ms. Julian and The Atlantic have placed on the rise in Alcohol Use Dysfunction (AUD), which has been exacerbated by the COVID-19 induced lockdowns—the ‘Second Pandemic of Dependancy,’ as additional highlighted in my current podcast interview with the Wall Street Resource.”

Key statistics relating to Alcohol Use Dysfunction embody:

  • In america, roughly 35 million folks every year endure from AUD, leading to important well being, social and monetary prices in response to the Nationwide Institute of Alcohol Abuse and Alcoholism (“NIAAA”) and Journal of the American Medical Affiliation (“JAMA”).
  • Extreme alcohol use is the third main reason for preventable dying and is chargeable for 31% of driving fatalities in america (NIAAA Alcohol Information & Statistics).
  • AUD contributes to over 200 totally different illnesses and 10% of youngsters reside with an individual that has an alcohol drawback (NIAAA Alcohol Information & Statistics).
  • 5-6% of latest cancers and most cancers deaths globally are immediately attributable to alcohol (American Society of Medical Oncologists).
  • Alcohol is the main reason for dying in folks ages 15-49 globally (The Lancet).
  • AUD prices america financial system about $250 billion yearly, with heavy consuming accounting for larger than 75% of the social and well being associated prices (The Facilities for Illness Management).
  • Solely 7.7% of sufferers, or roughly 2.7 million folks, with AUD are estimated to have been handled in any means and solely 3.6% by a doctor, or roughly 1.3 million folks (JAMA).
  • AUD in america seems to be rising with nearly a 50% improve in prevalence between 2002 and 2013 (JAMA).

About Adial Prescription drugs, Inc.

Adial Prescription drugs is a clinical-stage biopharmaceutical firm centered on creating therapies for the remedy and prevention of habit and associated issues. The Firm’s lead investigational new drug product, AD04, is a genetically focused, serotonin-3 receptor antagonist, therapeutic agent for the remedy of Alcohol Use Dysfunction (AUD) and is presently being investigated within the Firm’s landmark ONWARD™ pivotal Part 3 scientific trial for the potential remedy of AUD in topics with sure goal genotypes, that are to be recognized utilizing the Firm’s proprietary companion diagnostic genetic take a look at. A Part 2b scientific trial of AD04 for the remedy of AUD confirmed promising leads to lowering frequency of consuming, amount of consuming and heavy consuming (all with statistical significance), and no overt security considerations (there have been no statistically important severe adversarial occasions reported). AD04 can also be believed to have the potential to deal with different addictive issues resembling Opioid Use Dysfunction, playing, and weight problems, and the Firm develops adenosine analogs for the remedy of ache and different issues. Extra info is offered at www.adialpharma.com.

Concerning the Landmark ONWARD™ Pivotal Part 3 Medical Trial

The ONWARD trial is a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, Part 3 scientific research to guage the efficacy, security and tolerability of AD04 in sufferers with Alcohol Use Dysfunction (AUD) and chosen polymorphisms within the serotonin transporter and receptor genes. Sufferers are genetically screened previous to enrollment within the ONWARD trial in order that solely genetically optimistic sufferers are enrolled. The first endpoint for evaluation of efficacy is the change from baseline within the month-to-month variety of heavy consuming days over the last 8 weeks of the 24-week remedy interval. ONWARD is presently being carried out in 25 scientific websites in seven nations in Scandinavia and Central and Japanese Europe (Sweden, Finland, Poland, Latvia, Estonia, Bulgaria and Croatia). The principal investigator is Professor Hannu E.R. Alho, Emeritus Professor of Dependancy Medication on the College of Helsinki.

Ahead Trying Statements

This communication incorporates sure “forward-looking statements” throughout the which means of the U.S. federal securities legal guidelines. Such statements are primarily based upon numerous info and derived using quite a few necessary assumptions and are topic to identified and unknown dangers, uncertainties and different components which will trigger precise outcomes, efficiency or achievements to be materially totally different from any future outcomes, efficiency or achievements expressed or implied by such forward-looking statements. Statements preceded by, adopted by or that in any other case embody the phrases “believes,” “expects,” “anticipates,” “intends,” “initiatives,” “estimates,” “plans” and comparable expressions or future or conditional verbs resembling “will,” “ought to,” “would,” “could” and “may” are typically forward-looking in nature and never historic info, though not all forward-looking statements embody the foregoing. The forward-looking statements embody statements relating to the potential of AD04 to deal with different addictive issues resembling opioid use dysfunction, playing, and weight problems. Any forward-looking statements included herein replicate our present views, and so they contain sure dangers and uncertainties, together with, amongst others, our capability to leverage the acquisition of Purnovate and our different growth plans to place ourself as a pacesetter within the broader habit market, our capability to enroll sufferers throughout the timelines anticipated and full scientific trials on time and obtain desired outcomes and advantages as anticipated, the flexibility of AD04 to deal with different addictive issues resembling opioid use dysfunction, playing, and weight problems, our capability to acquire regulatory approvals for commercialization of product candidates or to adjust to ongoing regulatory necessities, regulatory limitations regarding our capability to advertise or commercialize our product candidates for particular indications, acceptance of its product candidates within the market and the profitable improvement, advertising and marketing or sale of merchandise, our capability to take care of our license agreements, the continued upkeep and development of our patent property, our capability to ascertain and keep collaborations, our capability to acquire or keep the capital or grants essential to fund its analysis and improvement actions, and our capability to retain our key staff or keep our Nasdaq itemizing. These dangers shouldn’t be construed as exhaustive and needs to be learn along with the opposite cautionary assertion included in our Annual Report on Type 10-Ok for the 12 months ended December 31, 2020, subsequent Quarterly Stories on Type 10-Q and present stories on Type 8-Ok filed with the Securities and Change Fee. Any forward-looking assertion speaks solely as of the date on which it was initially made. We undertake no obligation to publicly replace or revise any forward-looking assertion, whether or not on account of new info, future occasions, modified circumstances or in any other case, until required by regulation.

Contact:

Crescendo Communications, LLC

David Waldman / Natalya Rudman

Tel: 212-671-1021

E mail: adil@crescendo-ir.com



Primary Logo



Source link

Related posts

Leave a Comment